ALTMAN MICHAEL SETH
Insider CIK 1746738 · LYRA Director · ARYB Chief Financial Officer, Director · ARYA Chief Financial Officer, Director, 10% owner · ARYD Chief Financial Officer, Director, 10% owner · ARYE Chief Financial Officer, Director, 10% owner · ADGM 10% owner · PCSC Chief Business Officer, Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| FRNM Freenome, Inc. | C Conversion deriv | 2026-07-20 | 2026-07-22 | 2,066,250 | — | $0 | 0 | SEC↗ |
| FRNM Freenome, Inc. | C Conversion | 2026-07-20 | 2026-07-22 | 2,066,250 | — | $0 | 2,352,500 | SEC↗ |
| ADGM Adagio Medical Holdings, I | J Other | 2024-09-27 | 2024-10-01 | 3,501,600 | — | $0 | 0 | SEC↗ |
| ARYD ARYA Sciences Acquisition | D To issuer deriv | 2024-07-31 | 2024-07-31 | 2,647,500 | — | $0 | 0 | SEC↗ |
| ARYD ARYA Sciences Acquisition | D To issuer deriv | 2024-07-31 | 2024-07-31 | 1,000,000 | — | $0 | 2,647,500 | SEC↗ |
| ARYD ARYA Sciences Acquisition | D To issuer | 2024-07-31 | 2024-07-31 | 499,000 | — | $0 | 0 | SEC↗ |
| NAUT Nautilus Biotechnology, In | A Award deriv | 2024-06-14 | 2024-06-17 | 45,000 | — | $0 | 45,000 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | A Award deriv | 2024-06-13 | 2024-06-14 | 30,000 | — | $0 | 30,000 | SEC↗ |
| PCSC Perceptive Capital Solutio | A Award | 2024-06-13 | 2024-06-13 | 286,250 | $10.00 | $2.86M | 286,250 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | A Award deriv | 2023-06-30 | 2023-07-05 | 20,000 | — | $0 | 20,000 | SEC↗ |
| NAUT Nautilus Biotechnology, In | A Award deriv | 2023-06-15 | 2023-06-20 | 45,000 | — | $0 | 45,000 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | A Award deriv | 2022-06-16 | 2022-06-21 | 7,250 | — | $0 | 7,250 | SEC↗ |
| NAUT Nautilus Biotechnology, In | A Award deriv | 2022-06-15 | 2022-06-17 | 86,467 | — | $0 | 86,467 | SEC↗ |
| ARYE ARYA Sciences Acquisition | A Award | 2021-07-15 | 2021-07-15 | 499,000 | $10.00 | $4.99M | 499,000 | SEC↗ |
| [NAUT] Nautilus Biotechnology, In | C Conversion deriv | 2021-06-09 | 2021-06-11 | 3,647,500 | — | $0 | 0 | SEC↗ |
| [NAUT] Nautilus Biotechnology, In | A Award deriv | 2021-06-09 | 2021-06-11 | 44,435 | — | $0 | 44,435 | SEC↗ |
| [NAUT] Nautilus Biotechnology, In | C Conversion | 2021-06-09 | 2021-06-11 | 499,000 | — | $0 | 499,000 | SEC↗ |
| [NAUT] Nautilus Biotechnology, In | C Conversion | 2021-06-09 | 2021-06-11 | 3,647,500 | — | $0 | 3,647,500 | SEC↗ |
| [NAUT] Nautilus Biotechnology, In | C Conversion | 2021-06-09 | 2021-06-11 | 499,000 | — | $0 | 0 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | A Award deriv | 2021-05-26 | 2021-05-28 | 7,250 | — | $0 | 7,250 | SEC↗ |
| ARYD ARYA Sciences Acquisition | A Award | 2021-03-02 | 2021-03-02 | 499,000 | $10.00 | $4.99M | 499,000 | SEC↗ |
| ARYA ARYA Sciences Acquisition | J Other | 2020-08-11 | 2020-08-11 | 499,000 | $10.00 | $4.99M | 499,000 | SEC↗ |
| ARYB ARYA Sciences Acquisition | J Other | 2020-06-09 | 2020-06-09 | 499,000 | $10.00 | $4.99M | 499,000 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | A Award deriv | 2020-04-30 | 2020-05-01 | 14,500 | — | $0 | 14,500 | SEC↗ |